Related Experiment Video
Updated: Jan 24, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Limitations of Anti-Angiogenic Treatment of Tumors
Domenico Ribatti1, Tiziana Annese1, Simona Ruggieri1
1Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy.
Abstract:
Clinical trials using anti-vascular endothelial growth factor /(VEGF) molecules induce a modest improvement in overall survival, measurable in weeks to just a few months, and tumors respond differently to these agents. In this review article, we have exposed some tumor characteristics and processes that may impair the effectiveness of anti-angiogenic approaches, including genotypic changes on endothelial cells, the vascular normalization phenomenon, and the vasculogenic mimicry. The usage of anti-angiogenic molecules leads to hypoxic tumor microenvironment which enhances tumor invasiveness. The role of tumor-infiltrating cells, including tumor associated macrophages and fibroblasts (TAMs and TAFs) in the therapeutic response to anti-angiogenic settings was also highlighted. Finally, among the new therapeutic approaches to target tumor vasculature, anti-PD-1 or anti-PD-L1 therapy sensitizing and prolonging the efficacy of anti-angiogenic therapy, have been discussed.
Insights
Anti-angiogenic therapies show limited survival benefits. This review explores tumor traits like genetic changes and vascular mimicry that hinder anti-VEGF effectiveness, suggesting combination therapies for better outcomes.
Area of Science:
- Oncology
- Cancer Biology
- Tumor Microenvironment
Background:
- Anti-vascular endothelial growth factor (VEGF) therapies offer modest survival improvements in cancer treatment.
- Tumor responses to anti-angiogenic agents are variable, necessitating a deeper understanding of resistance mechanisms.
- The tumor microenvironment and cellular interactions significantly influence therapeutic efficacy.
Purpose of the Study:
- To review tumor characteristics and processes that compromise anti-angiogenic therapy effectiveness.
- To highlight the role of the hypoxic tumor microenvironment and tumor-infiltrating cells.
- To discuss novel therapeutic strategies, including immunotherapy combinations.
Main Methods:
- Literature review of clinical trials and preclinical studies on anti-angiogenic therapies.
- Analysis of tumor-specific factors influencing treatment response.
- Exploration of emerging therapeutic combinations targeting tumor vasculature.
Main Results:
- Tumor genotypic changes, vascular normalization, and vasculogenic mimicry can limit anti-VEGF efficacy.
- Anti-angiogenic treatment can induce a hypoxic microenvironment, potentially increasing tumor invasiveness.
- Tumor-associated macrophages (TAMs) and fibroblasts (TAFs) play a crucial role in anti-angiogenic therapy response.
Conclusions:
- Understanding resistance mechanisms is key to improving anti-angiogenic therapy outcomes.
- Combining anti-angiogenic therapy with agents like anti-PD-1/anti-PD-L1 may enhance efficacy and prolong survival.
- Targeting tumor vasculature requires a multifaceted approach considering tumor biology and immune interactions.
Related Concept Videos
Limiting Reactant
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
The Number e as a Limit
Central Limit Theorem
The sample size, n, that...
Limits to Natural Selection
Limits on Trigonometric Functions

